Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Enrolling by invitation Early Phase 1

Study on the Mechanism of Zuoqing San Promoting Postoperative Wound Healing of Anal Fistula by Inhibiting ROS-dependent NETosis

NCT07128953 · tracked via the Priya Life Science China tracker
Sponsor
The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Phase
Early Phase 1
Started
2025-08-01
Last updated
2025-08-19

Condition(s) studied

Anal Fistula

Investigational drug(s) / intervention(s)

Solution of Zuoqing San for fumigation and washing of the postoperative wound of anal fistulaEqual-volume placebo inhalation rinse

Solution of Zuoqing San for fumigation and washing of the postoperative wound of anal fistula: Left Qing San Decoction (25g of Cai Yin + 30g of Eucommia + 25g of Sophora flavescens + 25g of Anemarrhena asphodeloides + 15g of Lithospermum erythrorhizon, prepared in the Pharmacy Department of Anhui University of Traditional Chinese Medicine), add 1000mL of water, boil, then steam and wash the wound surface. The temperature is 40 ± 2℃. Do it once a day, for 15 minutes each time, for 7 consecutive days.

Equal-volume placebo inhalation rinse: Equal-volume placebo inhalation rinse

Study summary

This study adopted a randomized, double-blind, placebo-controlled clinical trial design to evaluate the efficacy and safety of Zuoqing San fumigation and washing on the wound healing after anal fistula surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Recurrent swelling and pain, along with pus discharge around the anus; * Preoperative MRI or ultrasound confirmed the presence of the fistula; * Underwent incision of the anal fistula, with the postoperative wound diameter ranging from 2 to 4 cm. Exclusion Criteria: 1. Inflammatory bowel disease (such as Crohn's disease) related anal fistula; 2. Complicated with severe dysfunction of heart, liver and kidney (ALT/AST \> 2 times upper limit, Cr \> 1.5 mg/dL); 3. Pregnant or lactating women; 4. Those who are known to be allergic to the components of Zuoqing San;

Primary outcome measure(s)

  • Wound healing time — From postoperative day 1 until wound healing is achieved (assessed daily during hospitalization and weekly after discharge, up to 8 weeks)
    The number of days from the day after the operation until the wound surface is completely covered by epithelium (as observed by the naked eye, there is no exudation, and upon palpation, the scar is smooth).

Trial sites (1)

FacilityCityRegionStatus
Anhui university of Chinese Medicine Hefei Anhui
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07128953 on ClinicalTrials.gov ↗ ← All trials in China